The American Association of Oral and Maxillofacial Surgeons (AAOMS) has released a Position Paper recommending the change in the nomenclature of “bisphosphonate-related osteonecrosis of the jaw (BRONJ)” to the more accurate term “medication-related osteonecrosis of the jaw (MRONJ)” and provided recommendations regarding risk/benefit analysis of medications and treatment guidance to clinicians.
The stated purpose of this updated position paper is to provide: risk estimates of developing MRONJ, comparisons of the risks and benefits of medications related to osteonecrosis of the jaw (ONJ) in order to facilitate medical decision-making for the treating physician, dentist, dental specialist, and patients. Additionally the paper will provide guidance to surgeons regarding: the differential diagnosis of MRONJ in patients with a history of exposure to antiresorptive and/or antiangiogenic agents and MRONJ prevention measures and management strategies for patients with MRONJ based on the disease stage.
